➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Dow
Colorcon
AstraZeneca
Johnson and Johnson

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 10,492,723

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,492,723
Title:Predicting immunotherapy response in non-small cell lung cancer patients with quantitative vessel tortuosity
Abstract: Embodiments classify a region of tissue demonstrating non-small cell lung cancer using quantified vessel tortuosity (QVT). One example apparatus includes annotation circuitry configured to segment a lung region from surrounding anatomy in the region of tissue represented in a radiological image and segment a nodule from the lung region by defining a nodule boundary; vascular segmentation circuitry configured to generate a three dimensional (3D) segmented vasculature by segmenting a vessel associated with the nodule, and to identify a center line of the 3D segmented vasculature; QVT feature extraction circuitry configured to extract a set of QVT features from the radiological image; and classification circuitry configured to compute a probability that the region of tissue will respond to immunotherapy and generate a classification that the region of tissue is a responder or a non-responder based, at least in part, on the probability.
Inventor(s): Madabhushi; Anant (Shaker Heights, OH), Alilou; Mehdi (Cleveland, OH), Velcheti; Vamsidhar (Pepper Pike, OH)
Assignee: Case Western Reserve University (Cleveland, OH)
Application Number:15/883,649
Patent Claims:see list of patent claims

Details for Patent 10,492,723

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck Sharp Dohme KEYTRUDA pembrolizumab POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER 125514 001 2014-09-04   Start Trial Case Western Reserve University (Cleveland, OH) 2037-02-27 RX Orphan search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125527 001 2015-03-04   Start Trial Case Western Reserve University (Cleveland, OH) 2037-02-27 RX search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125527 002 2015-03-04   Start Trial Case Western Reserve University (Cleveland, OH) 2037-02-27 RX search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125554 001 2015-11-23   Start Trial Case Western Reserve University (Cleveland, OH) 2037-02-27 RX Orphan search
Genentech Inc TECENTRIQ atezolizumab INJECTABLE;INJECTION 761034 001 2017-04-17   Start Trial Case Western Reserve University (Cleveland, OH) 2037-02-27 RX Orphan search
Genentech Inc TECENTRIQ atezolizumab INJECTABLE; INJECTION 761041 001 2016-10-18   Start Trial Case Western Reserve University (Cleveland, OH) 2037-02-27 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
McKinsey
Express Scripts
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.